- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
More ▼
Key statistics
On Friday, Kodiak Sciences Inc (KOD:NMQ) closed at 3.30, 140.88% above the 52 week low of 1.37 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.77 |
---|---|
High | 3.77 |
Low | 3.25 |
Bid | 3.23 |
Offer | 3.30 |
Previous close | 3.74 |
Average volume | 351.43k |
---|---|
Shares outstanding | 52.53m |
Free float | 49.56m |
P/E (TTM) | -- |
Market cap | 201.21m USD |
EPS (TTM) | -4.97 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼